Ascend Wellness Holdings (AAWH) Non-Current Debt (2020 - 2026)
Ascend Wellness Holdings (AAWH) posted quarterly Non-Current Debt of $292.3 million for Q1 2026, up 16.18% year-over-year from $251.6 million in Q1 2025, and down 8.52% quarter-over-quarter from $319.5 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Non-Current Debt (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Non-Current Debt history runs 7 years deep, the most recent figure standing at $292.3 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 16.18% year-over-year to $292.3 million; the TTM figure through Mar 2026 stood at $292.3 million (up 16.18% YoY), while the FY2025 annual figure was $319.5 million, up 3.73% from the prior year.
- Non-Current Debt for Q1 2026 stood at $292.3 million, down from $319.5 million in the prior quarter.
- The five-year high for Non-Current Debt was $343.7 million in Q3 2025, with the low at $222.6 million in Q1 2022.
- The 5-year median for Non-Current Debt is $297.6 million (2023), against an average of $293.3 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt surged 169.31% in 2022, then slipped 23.12% in 2024.
- Ascend Wellness Holdings' Non-Current Debt stood at $319.3 million in 2022, then retreated by 6.81% to $297.6 million in 2023, then increased by 3.51% to $308.0 million in 2024, then rose by 3.73% to $319.5 million in 2025, then slipped by 8.52% to $292.3 million in 2026.
- Business Quant data shows AAWH's Non-Current Debt at $292.3 million in Q1 2026, $319.5 million in Q4 2025, and $343.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 130.00 Mn |
| 10 | Ascend Wellness Holdings | 83.23 Mn | 16.23 Mn | 45.49 Mn | 334.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 334.36 Mn |
| Mar 31, 2026 | 292.31 Mn |
| Dec 31, 2025 | 319.52 Mn |
| Sep 30, 2025 | 343.75 Mn |
| Jun 30, 2025 | 323.44 Mn |
| Mar 31, 2025 | 251.61 Mn |
| Dec 31, 2024 | 308.02 Mn |
| Sep 30, 2024 | 232.16 Mn |
| Jun 30, 2024 | 289.53 Mn |
| Mar 31, 2024 | 288.70 Mn |
| Dec 31, 2023 | 297.57 Mn |
| Sep 30, 2023 | 301.99 Mn |
| Jun 30, 2023 | 300.78 Mn |
| Mar 31, 2023 | 321.42 Mn |
| Dec 31, 2022 | 319.30 Mn |
| Sep 30, 2022 | 290.97 Mn |
| Jun 30, 2022 | 282.05 Mn |
| Mar 31, 2022 | 222.59 Mn |
| Dec 31, 2021 | 230.85 Mn |
| Sep 30, 2021 | 230.50 Mn |